CD274 and neoplasm: Likewise, the FDA requires a PD-L1 positive tumor-infiltrating immune cells (IC) score of ≥5% for upfront treatment with atezolizumab, based on interim analysis of the IMvigor130 phase III trial (NCT02807636).